ライフサイエンスコーパス: amenorrhea

1 menopause in women with chemotherapy-induced amenorrhea.

2 s, 16 (26%) irregular bleeding, and 16 (26%) amenorrhea.

3 lar and unpredictable bleeding, and 19 (30%) amenorrhea.

4 truation disorders; premature menopause, and amenorrhea.

5 ived chemotherapy, 35% experienced long-term amenorrhea.

6 ceive chemotherapy, 5.3% developed long-term amenorrhea.

7 cts a genetic predisposition to hypothalamic amenorrhea.

8 oup without tamoxifen had the lowest rate of amenorrhea.

9 deficiency, are associated with hypothalamic amenorrhea.

10 nRH secretion that characterize hypothalamic amenorrhea.

11 eiving adjuvant chemotherapy are at risk for amenorrhea.

12 linical hyperandrogenism, oligomenorrhea, or amenorrhea.

13 rehensive evaluation of chemotherapy-induced amenorrhea.

14 er completion of chemotherapy, she developed amenorrhea.

15 ine, and prednisone (BEACOPP) had continuous amenorrhea.

16 ormone leptin and may result in hypothalamic amenorrhea.

17 ndocrine function in women with hypothalamic amenorrhea.

18 g their role in women with treatment-related amenorrhea.

19 s reported regular menses, and 4.6% reported amenorrhea.

20 of the LH protein and cause anovulation and amenorrhea.

21 a teenage girl with proteinuria and primary amenorrhea.

22 Amenorrhea 12 months after random assignment was signifi

23 adrenal insufficiency, two had a history of amenorrhea after birth of their children many years earl

24 We determined the age of onset of amenorrhea after breast cancer for women who were and we

25 Amenorrhea after therapy was most pronounced in women wi

26 are treated for advanced-stage HL experience amenorrhea after therapy.

27 were assessed concerning their influence on amenorrhea: age, treatment, stage, and the use of oral c

28 ineral density in patients with hypothalamic amenorrhea, an infertility syndrome in females.

29 Body weight combined with months of amenorrhea and age of menarche predicted the BMD of the

30 Duration of amenorrhea and body weight of amenorrheic athletes predi

31 e for pregnancy, ascertained by a history of amenorrhea and confirmed by urine test.

32 re ovarian failure (POF) is characterized by amenorrhea and high serum levels of follicle-stimulating

33 tory menstruation in women with hypothalamic amenorrhea and improves metabolic dysfunction in patient

34 with diet- or exercise-induced hypothalamic amenorrhea and lipoatrophy.

35 c hypogonadism in 55 women with hypothalamic amenorrhea and performed in vitro studies of the identif

36 a by treatment arm, the relationship between amenorrhea and QOL, and QOL by treatment arm.

37 tion in some women with chemotherapy-induced amenorrhea and should be used with caution.

38 ron donor for these enzymes, in a woman with amenorrhea and three children with ABS, even though knoc

39 iac iron was associated with the presence of amenorrhea and with NTBI levels.

40 s of prior studies of increased frequency of amenorrhea and/or irregular menstrual cycles, particular

41 ive pregnancy test, greater than 3 months of amenorrhea, and a follicle-stimulating hormone > or = 30

42 l axis such as delayed puberty, hypothalamic amenorrhea, and hypogonadotropic hypogonadism.

43 dex lt 10% for age, vitamin D insufficiency, amenorrhea, and low bone mass.

44 ent rates of permanent amenorrhea, temporary amenorrhea, and oligomenorrhea among different regimens;

45 Disordered eating, amenorrhea, and osteoporosis describe the "female athlet

46 Chronic renal failure leads to amenorrhea, and successful pregnancy is rare.

47 he possible benefits of chemotherapy-induced amenorrhea, and the challenges of interpreting the exist

48 leptin deficiency in women with hypothalamic amenorrhea appears to improve reproductive, thyroid, and

49 troducing foods at 4 mo on the likelihood of amenorrhea at 6 mo postpartum, but not thereafter, and t

50 with lowest lifetime weight and duration of amenorrhea, but there were no such associations with bon

51 Prespecified analyses examined rates of amenorrhea by treatment arm, the relationship between am

52 when the patient experienced >/= 2 years of amenorrhea, commencing within 2 years of initiating chem

53 hemotherapy; (2) define chemotherapy-related amenorrhea (CRA); (3) document rates of permanent amenor

54 The risk of induced long-term amenorrhea does not seem to be greater among mutation ca

55 Eight women with hypothalamic amenorrhea due to strenuous exercise or low weight were

56 nosis and who underwent chemotherapy-induced amenorrhea during adjuvant treatment.

57 erall survival was improved in patients with amenorrhea for 6 months or more across all treatment gro

58 e-aged multiparous female who presented with amenorrhea for three months.

59 ll for more than 6 years, risk ratio = 2.7), amenorrhea (for patients who had this symptom for more t

60 the histologic features and the presence of amenorrhea, galactorrhea, and an elevated serum prolacti

61 myelopathy from syringomyelia, paraparesis, amenorrhea-galactorrhea, and other endocrine problems, h

62 Hypothalamic amenorrhea (HA) is associated with dysfunction of the hy

63 Here, we studied 3 sisters with primary amenorrhea, hypothyroidism, and hypergonadotropic hypogo

64 ries each year and many experience temporary amenorrhea immediately following injury.

65 with lowest lifetime weight and duration of amenorrhea in anorexia nervosa.

66 ociated with an increased risk for sustained amenorrhea in these patients.

67 characterized by elevated gonadotropins and amenorrhea in women aged <40 years.

68 Chronic liver disease often leads to amenorrhea in women of childbearing age.

69 important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation.

70 riages: 72%; mean gestational age 39 days of amenorrhea) in the intention-to-treat analysis; 66.6% of

71 The incidence of hospitalization, amenorrhea, infections, nausea, and vomiting was signifi

72 = 40, hyperandrogenism and oligomenorrhea or amenorrhea), intermediate (n = 8, hyperandrogenism), or

73 Functional hypothalamic amenorrhea is a reversible form of gonadotropin-releasin

74 Chemotherapy-induced amenorrhea is a serious concern for women undergoing can

75 Amenorrhea is a well-recognized occurrence after chemoth

76 Amenorrhea is significantly more frequent in women with

77 Lactational amenorrhea (LA) is associated with postpartum infertilit

78 self-report of climacteric symptoms, and/or amenorrhea lasting >6 months, and/or oophorectomy, and/o

79 in menstrual flow amount or duration; or (3) amenorrhea lasting at least 3 months.

80 for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertilit

81 Extended periods of amenorrhea may result in low bone density at multiple sk

82 lly accepted indicators of pregnancy include amenorrhea, morning sickness, tender or tingling breasts

83 Amenorrhea occurred frequently as a result of treatment

84 verage of 5 years until at least 6 months of amenorrhea occurred.

85 ea were 73%, 82%, and 6%, respectively, with amenorrhea occurring within 10 days in the majority of p

86 However, the impact of chemotherapy-induced amenorrhea on prognosis is still being defined.

87 ion of hormone therapy prior to 12 months of amenorrhea (OR = 2.94, 95% CI: 1.14, 7.58; P = 0.03).

88 ous genitalia, prepubertal bleeding, primary amenorrhea, pelvic mass, and pelvic pain.

89 Amenorrhea rates differed significantly by treatment arm

90 ogen receptor status, and treatment regimen, amenorrhea rates on triptorelin were comparable to those

91 Six control subjects with hypothalamic amenorrhea received no treatment and were studied for a

92 Adverse events were amenorrhea (seen in 41% of the cyclophosphamide group, 4

93 s families with daughters exhibiting primary amenorrhea, short stature, and a 46,XX karyotype.

94 onadism are found in women with hypothalamic amenorrhea, suggesting that these mutations may contribu

95 drogenism), or low (n = 7, oligomenorrhea or amenorrhea) suspicion of PCOS.

96 rrhea (CRA); (3) document rates of permanent amenorrhea, temporary amenorrhea, and oligomenorrhea amo

97 We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced

98 als with manifestations ranging from primary amenorrhea to loss of menstrual function prior to age 40

99 ed in 7 of the 55 patients with hypothalamic amenorrhea: two variants in the fibroblast growth factor

100 of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hy

101 The rate of chemotherapy-induced amenorrhea varies with patient age and chemotherapy regi

102 At follow-up, the rate of amenorrhea was 16.8% (2.9% because of pregnancy).

103 Amenorrhea was associated with improved survival regardl

104 The probability of induced amenorrhea was higher for women who received tamoxifen t

105 Amenorrhea was significantly more frequent after dose-es

106 Median times to amenorrhea were 7 days for patients receiving 5 mg of ul

107 The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age 30 y

108 The rates of amenorrhea were 73%, 82%, and 6%, respectively, with ame

109 al Disorders, Fourth Edition, AN (except for amenorrhea) were enrolled.

110 This review will discuss the incidence of amenorrhea with commonly-used adjuvant chemotherapeutic

111 ere to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women.

112 experiencing the female triad (hypothalamic amenorrhea) with acquired chronic hypoleptinemia induced